VRCA · XBRL financial data

Verrica Pharmaceuticals financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (VRCA's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24†Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25†Jun 30, 2025	Q3 FY25†Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue	—	—	—	—	(1,781)	344*	3,439	12,702	14,344	5,092*	5,023	5,862
Revenue from contracts with customers	2,917	1,988*	3,826	5,177	(1,781)	344*	3,439	12,702	—	—	—	—
Cost of revenue	300	200*	700	700	400	800*	700	—	—	—	—	—
Research and development	6,510	5,320*	4,948	3,319	2,405	1,167*	2,284	1,846	2,205	2,520*	3,860	6,034
Selling, general and administrative	20,054	16,995*	16,339	16,522	16,083	9,879*	8,848	8,852	9,403	8,117*	9,989	10,349
Total operating expenses	26,834	25,124*	22,425	20,383	18,923	11,754*	11,569	11,192	12,717	12,284*	14,738	18,959
Operating income (loss)	(23,917)	(23,136)*	(18,599)	(15,206)	(20,704)	(11,410)*	(8,130)	1,510	1,627	(7,192)*	(9,715)	(13,097)
Interest income	822	792*	598	393	221	205*	337	228	159	205*	201	111
Interest expense	1,657	2,305*	2,319	2,368	2,376	2,349*	2,203	2,131	2,094	1,314*	160	164
Other income (expense)	(50)	35*	(11)	(5)	(1)	0*	0	(1)	0	(2)*	(8)	(3)
Income tax expense (benefit)	—	year only	—	—	—	year only	—	—	—	year only	—	—
Net income (loss)	(24,802)	(24,614)*	(20,331)	(17,186)	(22,860)	(16,202)*	(9,742)	204	(274)	(8,074)*	(9,682)	(13,153)
Earnings per share, basic‡ USD per share	(5.40)	(5.30)*	(4.40)	(3.70)	(4.90)	—	(1.00)	0.20	(0.03)	—	(0.45)	(0.62)
Earnings per share, diluted‡ USD per share	(5.40)	(5.30)*	(4.40)	(3.70)	(4.90)	—	(1.00)	0.20	(0.03)	—	(0.45)	(0.62)
Weighted average shares, basic‡ thousands of shares	4,607	4,631*	4,648	4,650	4,681	—	9,484	949	9,490	—	21,305	21,305
Weighted average shares, diluted‡ thousands of shares	4,607	4,631*	4,648	4,650	4,681	—	9,484	949	9,490	—	21,305	21,305

‡ Per-share figures and share counts are adjusted for the 1-for-10 stock split (July 2025); filings made before it reported them unadjusted.
† Share count changed about 2x in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 1/10 in the period ending 2025-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 10x in the period ending 2025-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (VRCA's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24†Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25†Jun 30, 2025	Q3 FY25†Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	84,308	69,547	48,939	31,930	22,959	46,329	29,595	15,396	21,097	30,147	20,600	11,198
Accounts receivable	3,946	4,248	7,002	10,026	0	48	5,607	9,193	7,047	5,260	7,724	10,939
Inventory	279	1,022	2,499	2,704	2,584	2,463	2,459	2,522	2,304	2,236	1,974	2,712
Prepaid and other current assets	3,066	2,545	2,344	2,476	2,560	2,310	1,767	1,492	3,586	2,801	2,368	2,619
Total current assets	91,725	77,530	61,376	47,318	28,187	51,179	39,474	36,781	36,275	42,539	34,129	32,639
Property and equipment, net	3,558	1,052	937	710	651	589	537	315	225	209	191	177
Right-of-use asset	1,339	1,158	1,082	1,005	912	836	764	690	616	540	463	384
Total assets	97,148	81,597	66,307	52,010	32,927	54,134	42,178	39,107	40,896	47,131	38,786	36,017
Accounts payable	1,925	2,464	2,527	1,150	966	1,896	1,443	2,321	1,585	2,072	2,193	1,603
Current portion of long-term debt	—	0	—	—	—	12,938	12,821	12,673	12,458	0	—	—
Total current liabilities	11,374	17,024	19,365	20,051	21,026	29,012	29,396	29,222	28,908	16,437	16,219	22,442
Lease liability, non-current	989	910	825	744	665	583	500	416	330	242	152	61
Total liabilities	54,845	61,834	64,799	65,310	66,978	63,994	60,754	56,591	57,936	22,388	22,731	31,710
Accumulated deficit	(205,834)	(230,448)	(250,779)	(267,965)	(290,825)	(307,027)	(316,769)	(316,565)	(316,839)	(324,913)	(334,595)	(347,748)
Total stockholders' equity	42,303	19,763	1,508	(13,300)	(34,051)	(9,860)	(18,576)	(17,484)	(17,040)	24,743	16,055	4,307
Total liabilities and equity	97,148	81,597	66,307	52,010	32,927	54,134	42,178	39,107	40,896	47,131	38,786	36,017
Common shares outstanding (cover page)‡ thousands of shares	4,206	4,242	4,242	4,267	4,560	9,178	9,249	945	9,490	17,179	17,179	17,179

‡ Per-share figures and share counts are adjusted for the 1-for-10 stock split (July 2025); filings made before it reported them unadjusted.
† Share count changed about 2x in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 1/10 in the period ending 2025-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 10x in the period ending 2025-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (VRCA's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24†Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25†Jun 30, 2025	Q3 FY25†Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(24,802)	(24,614)*	(20,331)	(17,186)	(22,860)	(16,202)*	(9,742)	204	(274)	(8,074)*	(9,682)	(13,153)
Net cash from operating activities	(14,811)*	(14,507)*	(19,947)	(16,358)*	(8,558)*	(16,064)*	(12,677)	(10,044)*	9,685*	(4,591)*	(9,163)	(9,278)*
Purchases of property and equipment	65*	227*	0	11*	16*	0*	—	—	0*	0*	—	—
Net cash from investing activities	(65)*	(227)*	0	(11)*	(16)*	8*	0	0*	0*	0*	0	0*
Proceeds from issuing common stock	0*	—	—	—	—	—	—	—	—	—	—	—
Net cash from financing activities	44,044*	(27)*	(661)	(640)*	(397)*	39,426*	(4,057)	(4,155)*	(3,984)*	13,641*	(120)	(126)*
Net change in cash	29,168*	(14,761)*	(20,608)	(17,009)*	(8,971)*	23,370*	(16,734)	(14,199)*	5,701*	9,050*	(9,283)	(9,404)*

† Share count changed about 2x in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 1/10 in the period ending 2025-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 10x in the period ending 2025-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Verrica Pharmaceuticals	11,198	5,862	(9,278)*	17.2M	1.2 quarters	Q2 FY26 10-QJun 30, 2026
Outlook Therapeutics	11,242	not reported	(21,011)*	243.4M	0.5 quarters	Q3 FY26 10-QJun 30, 2026
OnKure Therapeutics	166,502	not reported	(10,354)*	40.5M	17.0 quarters	Q2 FY26 10-QJun 30, 2026
Champions Oncology	4,358	15,232	(492)	13.9M	8.0 quarters	Q1 FY27 10-QJul 31, 2026
Rockwell Medical	10,519	not reported	2,080*	4.0M	—	Q2 FY26 10-QJun 30, 2026
Palatin Technologies	7,492	301*	(2,690)*	1.8M	2.8 quarters	Q4 FY26 10-KJun 30, 2026
Scynexis	10,487	235	(14,885)*	9.9M	3.6 quarters	Q2 FY26 10-QJun 30, 2026
Cumberland Pharmaceuticals	3,862	166	169*	15.0M	—	Q2 FY26 10-QJun 30, 2026
Pulmatrix	2,168	not reported	(1,106)*	3.7M	2.0 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.